Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2017

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Buprenorphine transdermal patch (Butec®) has been accepted for restricted use in adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. The restriction limits use to elderly patients (over 65 years).

Conjugated oestrogens and bazedoxifene acetate (Duavive®) has been rejected in the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2017' on Email Share 'SMC Update - January 2017' on Delicious Share 'SMC Update - January 2017' on Digg Share 'SMC Update - January 2017' on Facebook Share 'SMC Update - January 2017' on Google+ Share 'SMC Update - January 2017' on reddit Share 'SMC Update - January 2017' on StumbleUpon Share 'SMC Update - January 2017' on Twitter

atomic-wealth

No Comments to “SMC Update - January 2017”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,278 spam comments.

atomic-wealth
fond-illness
summer